survivin-T34A

Survivin-T34A is a **mutant form of the human protein survivin**, engineered by substituting threonine 34 with alanine, which abrogates a key phosphorylation site required for survivin’s anti-apoptotic function[2][1][4]. Unlike wild-type survivin, which inhibits apoptosis and supports cell division, survivin-T34A acts as a **dominant-negative** protein that induces mitochondrial apoptosis and cell death selectively in cancer cells that express survivin, with little effect on normal cells[2][3][4]. This mutant has been delivered as a gene therapy (e.g., via adenoviral or plasmid vectors) or purified protein fused to a cell-penetrating domain (such as TATm-survivin-T34A)[1], showing robust antitumor activity in multiple preclinical models, reduction in tumor angiogenesis, and enhancement of chemosensitivity and radiosensitivity[1][2][4][3][5]. Survivin-T34A is studied primarily for **anticancer therapy**, often in solid tumors like breast, cervical, liver, lung, pancreatic, and colorectal cancers[1][2][4][5]. Developers have included academic groups investigating protein- and gene-based delivery systems.

Other names

mutant survivin T34ATATm-survivin T34APST34APST-34APST 34A